Skip to Main Content

Paper Details

A phase 2 study of simtuzumab in patients with primary, post-polycythaemia vera or post-essential thrombocythaemia myelofibrosis.
Br J Haematol
38
2017
Author NameAffiliation
Stephen T OhWashington University School of Medicine
Jason GotlibStanford University School of Medicine/Stanford Cancer Institute
  • 1 - 2

Datasets

Release 1.2